AI Article Synopsis
- SARS-CoV-2 mRNA vaccines, like the Moderna vaccine, show high effectiveness, but individual immune responses can vary, especially in antibody production.
- Researchers studied the immune response in adults, finding strong antibody responses (IgA and IgG) that were linked to the activation of spike-specific plasmablasts, which were notably more intense after the second vaccine dose.
- They also discovered different types of memory B cells (MBC) that appeared at various times post-vaccination, suggesting that certain immune markers before and after vaccination could predict how well someone might respond to the vaccine in terms of antibody levels.
Article Abstract
SARS-CoV-2 mRNA vaccines are highly effective, although weak antibody responses are seen in some individuals with correlates of immunity that remain poorly understood. Here we longitudinally dissected antibody, plasmablast, and memory B cell (MBC) responses to the two-dose Moderna mRNA vaccine in SARS-CoV-2-uninfected adults. Robust, coordinated IgA and IgG antibody responses were preceded by bursts of spike-specific plasmablasts after both doses, but earlier and more intensely after dose two. Distinct antigen-specific MBC populations also emerged post-vaccination with varying kinetics. We identified antigen non-specific pre-vaccination MBC and post-vaccination plasmablasts after dose one and their spike-specific counterparts early after dose two that correlated with subsequent antibody levels. These baseline and response signatures can thus provide early indicators of serological efficacy and explain response variability in the population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282109 | PMC |
| http://dx.doi.org/10.1101/2021.07.06.21259528 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!